P2RY12 and diabetes mellitus: Noteworthy, recent evidence points toward a potential benefit of personalized antiplatelet therapy using platelet function of genetic assessment (e.g., guided escalation of P2Y12 inhibitors) in the PCI setting, which may be of particular relevance in DM patients due to the heightened platelet reactivity and the high rates of clopidogrel suboptimal response that characterize this population (41, 42).